Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 433

1.

Long-term colorectal cancer incidence after adenoma removal and the effects of surveillance on incidence: a multicentre, retrospective, cohort study.

Cross AJ, Robbins EC, Pack K, Stenson I, Kirby PL, Patel B, Rutter MD, Veitch AM, Saunders BP, Duffy SW, Wooldrage K.

Gut. 2020 Jan 17. pii: gutjnl-2019-320036. doi: 10.1136/gutjnl-2019-320036. [Epub ahead of print]

2.

Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients.

Blyuss O, Zaikin A, Cherepanova V, Munblit D, Kiseleva EM, Prytomanova OM, Duffy SW, Crnogorac-Jurcevic T.

Br J Cancer. 2019 Dec 20. doi: 10.1038/s41416-019-0694-0. [Epub ahead of print]

PMID:
31857725
3.

Lung Screen Uptake Trial (LSUT): Randomised Controlled Trial Testing Targeted Invitation Materials.

Quaife SL, Ruparel M, Dickson JL, Beeken RJ, McEwen A, Baldwin DR, Bhowmik A, Navani N, Sennett K, Duffy SW, Waller J, Janes SM.

Am J Respir Crit Care Med. 2019 Dec 11. doi: 10.1164/rccm.201905-0946OC. [Epub ahead of print]

PMID:
31825647
4.

Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines.

Schünemann HJ, Lerda D, Quinn C, Follmann M, Alonso-Coello P, Rossi PG, Lebeau A, Nyström L, Broeders M, Ioannidou-Mouzaka L, Duffy SW, Borisch B, Fitzpatrick P, Hofvind S, Castells X, Giordano L, Canelo-Aybar C, Warman S, Mansel R, Sardanelli F, Parmelli E, Gräwingholt A, Saz-Parkinson Z; European Commission Initiative on Breast Cancer (ECIBC) Contributor Group.

Ann Intern Med. 2019 Nov 26. doi: 10.7326/M19-2125. [Epub ahead of print]

PMID:
31766052
5.

Sporadic implementation of UK familial mammographic surveillance guidelines 15 years after original publication.

Evans DG, Edwards M, Duffy SW; Cancer Genetics Group clinical leads, Tischkowitz M.

Br J Cancer. 2019 Nov 25. doi: 10.1038/s41416-019-0631-2. [Epub ahead of print]

PMID:
31761901
6.

Erratum to "Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme" [Lung Cancer 134 (August) (2019) 66-71].

Ghimire B, Maroni R, Vulkan D, Shah Z, Gaynor E, Timoney M, Jones L, Arvanitis R, Ledson M, Lukehirst L, Rutherford P, Clarke F, Gardner K, Marcus MW, Hill S, Fidoe D, Mason S, Smith SG, Quaife SL, Fitzgerald K, Poirier V, Duffy SW, Field JK.

Lung Cancer. 2020 Jan;139:224. doi: 10.1016/j.lungcan.2019.10.007. Epub 2019 Nov 2. No abstract available.

PMID:
31690469
7.

A compact system for intraoperative specimen imaging based on edge illumination x-ray phase contrast.

Havariyoun G, Vittoria FA, Hagen CK, Basta D, Kallon GK, Endrizzi M, Massimi L, Munro P, Hawker S, Smit B, Astolfo A, Larkin OJ, Waltham RM, Shah Z, Duffy SW, Nelan RL, Peel A, Suaris T, Jones JL, Haig IG, Bate D, Olivo A.

Phys Med Biol. 2019 Nov 26;64(23):235005. doi: 10.1088/1361-6560/ab4912.

PMID:
31569079
8.

Evaluation of cardiovascular risk in a lung cancer screening cohort.

Ruparel M, Quaife SL, Dickson JL, Horst C, Burke S, Taylor M, Ahmed A, Shaw P, Soo MJ, Nair A, Devaraj A, O'Dowd EL, Bhowmik A, Navani N, Sennett K, Duffy SW, Baldwin DR, Sofat R, Patel RS, Hingorani A, Janes SM.

Thorax. 2019 Dec;74(12):1140-1146. doi: 10.1136/thoraxjnl-2018-212812. Epub 2019 Sep 26.

9.

Impact of choice of volumetry software and nodule management guidelines on recall rates in lung cancer screening.

Soo E, Edey AJ, Mak SM, Moser J, Mohammadi S, Rodrigues T, Duffy SW, Field JK, Baldwin DR, Nair A, Devaraj A.

Eur J Radiol. 2019 Nov;120:108646. doi: 10.1016/j.ejrad.2019.108646. Epub 2019 Sep 8.

PMID:
31526892
10.

Concurrent participation in screening for cervical, breast, and bowel cancer in England.

Rebolj M, Parmar D, Maroni R, Blyuss O, Duffy SW.

J Med Screen. 2019 Sep 16:969141319871977. doi: 10.1177/0969141319871977. [Epub ahead of print] No abstract available.

PMID:
31525303
11.

Methods for Development of the European Commission Initiative on Breast Cancer Guidelines: Recommendations in the Era of Guideline Transparency.

Schünemann HJ, Lerda D, Dimitrova N, Alonso-Coello P, Gräwingholt A, Quinn C, Follmann M, Mansel R, Sardanelli F, Rossi PG, Lebeau A, Nyström L, Broeders M, Ioannidou-Mouzaka L, Duffy SW, Borisch B, Fitzpatrick P, Hofvind S, Castells X, Giordano L, Warman S, Saz-Parkinson Z; European Commission Initiative on Breast Cancer Contributor Group.

Ann Intern Med. 2019 Jul 23. doi: 10.7326/M18-3445. [Epub ahead of print]

PMID:
31330534
12.

Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme.

Ghimire B, Maroni R, Vulkan D, Shah Z, Gaynor E, Timoney M, Jones L, Arvanitis R, Ledson M, Lukehirst L, Rutherford P, Clarke F, Gardner K, Marcus MW, Hill S, Fidoe D, Mason S, Smith SG, Quaife SL, Fitzgerald K, Poirier V, Duffy SW, Field JK.

Lung Cancer. 2019 Aug;134:66-71. doi: 10.1016/j.lungcan.2019.05.026. Epub 2019 May 29. Erratum in: Lung Cancer. 2020 Jan;139:224.

PMID:
31319997
13.

Long-term excess risk of breast cancer after a single breast density measurement.

Rebolj M, Blyuss O, Chia KS, Duffy SW.

Eur J Cancer. 2019 Aug;117:41-47. doi: 10.1016/j.ejca.2019.05.009. Epub 2019 Jun 21.

14.

Imaging Biomarkers as Predictors for Breast Cancer Death.

Wu WY, Tabar L, Tot T, Fann CY, Yen AM, Chen SL, Chiu SY, Ku MM, Hsu CY, Beckmann KR, Smith RA, Duffy SW, Chen HH.

J Oncol. 2019 Apr 10;2019:2087983. doi: 10.1155/2019/2087983. eCollection 2019.

15.

Probability of cancer in lung nodules using sequential volumetric screening up to 12 months: the UKLS trial.

Marcus MW, Duffy SW, Devaraj A, Green BA, Oudkerk M, Baldwin D, Field J.

Thorax. 2019 Aug;74(8):761-767. doi: 10.1136/thoraxjnl-2018-212263. Epub 2019 Apr 26.

PMID:
31028232
16.

Towards evidence-based follow-up intervals for breast cancer survivors: Estimates of the preclinical detectable phase of contralateral second breast cancer.

Aarts AMWM, Duffy SW, Geurts SME, Vulkan DP, Houssami N, Zappa M, Nagtegaal ID, Verbeek ALM, Broeders MJM.

Breast. 2019 Jun;45:70-74. doi: 10.1016/j.breast.2019.03.003. Epub 2019 Mar 8.

PMID:
30884341
17.

Reply to The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening.

Duffy SW, Smith RA, Tabár L, Dean PB, Chen TH.

Cancer. 2019 Jun 15;125(12):2130-2131. doi: 10.1002/cncr.32007. Epub 2019 Feb 12. No abstract available.

PMID:
30747993
18.

Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study.

Atkin W, Cross AJ, Kralj-Hans I, MacRae E, Piggott C, Pearson S, Wooldrage K, Brown J, Lucas F, Prendergast A, Marchevsky N, Patel B, Pack K, Howe R, Skrobanski H, Kerrison R, Swart N, Snowball J, Duffy SW, Morris S, von Wagner C, Halloran S.

Health Technol Assess. 2019 Jan;23(1):1-84. doi: 10.3310/hta23010.

19.

Test sensitivity of mammography and mean sojourn time over 40 years of breast cancer screening in Nijmegen (The Netherlands).

Aarts A, Duffy SW, Geurts S, Vulkan DP, Otten J, Hsu CY, Chen T, Verbeek A, Broeders M.

J Med Screen. 2019 Sep;26(3):147-153. doi: 10.1177/0969141318814869. Epub 2018 Dec 12. No abstract available.

PMID:
30541383
20.

Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: a diagnostic accuracy and cost-effectiveness study.

Cross AJ, Wooldrage K, Robbins EC, Kralj-Hans I, MacRae E, Piggott C, Stenson I, Prendergast A, Patel B, Pack K, Howe R, Swart N, Snowball J, Duffy SW, Morris S, von Wagner C, Halloran SP, Atkin WS.

Gut. 2019 Sep;68(9):1642-1652. doi: 10.1136/gutjnl-2018-317297. Epub 2018 Dec 11.

21.

Risk stratification in breast screening: A word of caution.

Duffy SW.

J Med Screen. 2019 Jun;26(2):57-58. doi: 10.1177/0969141318813387. Epub 2018 Nov 18. No abstract available.

PMID:
30449245
22.

The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening.

Tabár L, Dean PB, Chen TH, Yen AM, Chen SL, Fann JC, Chiu SY, Ku MM, Wu WY, Hsu CY, Chen YC, Beckmann K, Smith RA, Duffy SW.

Cancer. 2019 Feb 15;125(4):515-523. doi: 10.1002/cncr.31840. Epub 2018 Nov 8.

23.

Reply to 'Comment on 'Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis".

Rebolj M, Brentnall A, Duffy SW.

Br J Cancer. 2018 Nov;119(11):1444. doi: 10.1038/s41416-018-0247-y. Epub 2018 Nov 9. No abstract available.

24.

The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review.

Broeders MJM, Allgood P, Duffy SW, Hofvind S, Nagtegaal ID, Paci E, Moss SM, Bucchi L.

BMC Cancer. 2018 Sep 3;18(1):860. doi: 10.1186/s12885-018-4666-1. Review.

25.

Lung cancer CT screening: are we ready to consider screening biennially in a subgroup of low-risk individuals?

Field JK, Duffy SW.

Thorax. 2018 Nov;73(11):1006-1007. doi: 10.1136/thoraxjnl-2018-211814. Epub 2018 Jun 28. No abstract available.

PMID:
29954858
26.

Trends in lung cancer emergency presentation in England, 2006-2013: is there a pattern by general practice?

Maringe C, Pashayan N, Rubio FJ, Ploubidis G, Duffy SW, Rachet B, Raine R.

BMC Cancer. 2018 May 31;18(1):615. doi: 10.1186/s12885-018-4476-5.

27.

Patient selection for future lung cancer computed tomography screening programmes: lessons learnt post National Lung Cancer Screening Trial.

Field JK, Duffy SW, Baldwin DR.

Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S114-S116. doi: 10.21037/tlcr.2018.03.12. No abstract available.

28.

Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis.

Rebolj M, Assi V, Brentnall A, Parmar D, Duffy SW.

Br J Cancer. 2018 Jun;118(12):1559-1570. doi: 10.1038/s41416-018-0080-3. Epub 2018 May 8.

29.

Association between Screening Mammography Recall Rate and Interval Cancers in the UK Breast Cancer Service Screening Program: A Cohort Study.

Burnside ES, Vulkan D, Blanks RG, Duffy SW.

Radiology. 2018 Jul;288(1):47-54. doi: 10.1148/radiol.2018171539. Epub 2018 Apr 3.

30.

Low-dose CT for lung cancer screening - Authors' reply.

Field JK, Heuvelmans MA, Devaraj A, Heussel CP, Baldwin DR, Vliegenthart R, Duffy SW, Oudkerk M.

Lancet Oncol. 2018 Mar;19(3):e135-e136. doi: 10.1016/S1470-2045(18)30122-0. No abstract available.

PMID:
29508758
31.

European position statement on lung cancer screening.

Oudkerk M, Devaraj A, Vliegenthart R, Henzler T, Prosch H, Heussel CP, Bastarrika G, Sverzellati N, Mascalchi M, Delorme S, Baldwin DR, Callister ME, Becker N, Heuvelmans MA, Rzyman W, Infante MV, Pastorino U, Pedersen JH, Paci E, Duffy SW, de Koning H, Field JK.

Lancet Oncol. 2017 Dec;18(12):e754-e766. doi: 10.1016/S1470-2045(17)30861-6. Review.

PMID:
29208441
32.

Mammographic density and breast cancer risk in breast screening assessment cases and women with a family history of breast cancer.

Duffy SW, Morrish OWE, Allgood PC, Black R, Gillan MGC, Willsher P, Cooke J, Duncan KA, Michell MJ, Dobson HM, Maroni R, Lim YY, Purushothaman HN, Suaris T, Astley SM, Young KC, Tucker L, Gilbert FJ.

Eur J Cancer. 2018 Jan;88:48-56. doi: 10.1016/j.ejca.2017.10.022. Epub 2017 Nov 27.

33.

Fear, family and the placing of emotion: Black women's responses to a breast cancer awareness intervention.

Brown T, Dyck I, Greenhough B, Raven-Ellison M, Dembinsky M, Ornstein M, Duffy SW.

Soc Sci Med. 2017 Dec;195:90-96. doi: 10.1016/j.socscimed.2017.10.037. Epub 2017 Nov 20.

PMID:
29156250
34.

Effect of Mammography Screening on Mortality by Histological Grade.

Tabar L, Chen TH, Yen AM, Chen SL, Fann JC, Chiu SY, Ku MMS, Wu WY, Hsu CY, Chen YY, Beckmann K, Smith RA, Duffy SW.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):154-157. doi: 10.1158/1055-9965.EPI-17-0487. Epub 2017 Nov 17.

35.

Impact of radiographer immediate reporting of chest X-rays from general practice on the lung cancer pathway (radioX): study protocol for a randomised control trial.

Woznitza N, Devaraj A, Janes SM, Duffy SW, Bhowmik A, Rowe S, Piper K, Maughn S, Baldwin DR.

Trials. 2017 Nov 6;18(1):521. doi: 10.1186/s13063-017-2268-x.

36.

Breast Cancer Screening in Denmark.

Chen THH, Duffy SW.

Ann Intern Med. 2017 Oct 3;167(7):523-524. doi: 10.7326/L17-0267. No abstract available.

PMID:
28973197
37.

Reducing the socioeconomic gradient in uptake of the NHS bowel cancer screening Programme using a simplified supplementary information leaflet: a cluster-randomised trial.

Smith SG, Wardle J, Atkin W, Raine R, McGregor LM, Vart G, Morris S, Duffy SW, Moss S, Hackshaw A, Halloran S, Kralj-Hans I, Howe R, Snowball J, Handley G, Logan RF, Rainbow S, Smith S, Thomas M, Counsell N, von Wagner C.

BMC Cancer. 2017 Aug 14;17(1):543. doi: 10.1186/s12885-017-3512-1.

38.

Colorectal adenomas, surveillance, and cancer - Authors' reply.

Atkin W, Wooldrage K, Sasieni P, Duffy SW, Cross AJ.

Lancet Oncol. 2017 Aug;18(8):e428. doi: 10.1016/S1470-2045(17)30532-6. Epub 2017 Jul 26. No abstract available.

39.

The impact of trained radiographers as concurrent readers on performance and reading time of experienced radiologists in the UK Lung Cancer Screening (UKLS) trial.

Nair A, Screaton NJ, Holemans JA, Jones D, Clements L, Barton B, Gartland N, Duffy SW, Baldwin DR, Field JK, Hansell DM, Devaraj A.

Eur Radiol. 2018 Jan;28(1):226-234. doi: 10.1007/s00330-017-4903-z. Epub 2017 Jun 22.

40.

The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations.

Atkin W, Brenner A, Martin J, Wooldrage K, Shah U, Lucas F, Greliak P, Pack K, Kralj-Hans I, Thomson A, Perera S, Wood J, Miles A, Wardle J, Kearns B, Tappenden P, Myles J, Veitch A, Duffy SW.

Health Technol Assess. 2017 Apr;21(25):1-536. doi: 10.3310/hta21250.

41.

Screening organization and recall rate in a regional breast screening programme.

Beruchashwili T, Gvamichava R, Duffy SW.

J Med Screen. 2018 Mar;25(1):55-56. doi: 10.1177/0969141317704680. Epub 2017 Jun 14.

PMID:
28614990
42.

GP participation in increasing uptake in a national bowel cancer screening programme: the PEARL project.

Benton SC, Butler P, Allen K, Chesters M, Rickard S, Stanley S, Roope R, Vulkan D, Duffy SW.

Br J Cancer. 2017 Jun 6;116(12):1551-1557. doi: 10.1038/bjc.2017.129. Epub 2017 May 18.

43.

Effect of second timed appointments for non-attenders of breast cancer screening in England: a randomised controlled trial.

Allgood PC, Maroni R, Hudson S, Offman J, Turnbull AE, Peacock L, Steel J, Kirby G, Ingram CE, Somers J, Fuller C, Threlfall AG, Gabe R, Maxwell AJ, Patnick J, Duffy SW.

Lancet Oncol. 2017 Jul;18(7):972-980. doi: 10.1016/S1470-2045(17)30340-6. Epub 2017 May 15.

44.

Adenoma surveillance and colorectal cancer incidence: a retrospective, multicentre, cohort study.

Atkin W, Wooldrage K, Brenner A, Martin J, Shah U, Perera S, Lucas F, Brown JP, Kralj-Hans I, Greliak P, Pack K, Wood J, Thomson A, Veitch A, Duffy SW, Cross AJ.

Lancet Oncol. 2017 Jun;18(6):823-834. doi: 10.1016/S1470-2045(17)30187-0. Epub 2017 Apr 28.

45.

Does Reader Performance with Digital Breast Tomosynthesis Vary according to Experience with Two-dimensional Mammography?

Tucker L, Gilbert FJ, Astley SM, Dibden A, Seth A, Morel J, Bundred S, Litherland J, Klassen H, Lip G, Purushothaman H, Dobson HM, McClure L, Skippage P, Stoner K, Kissin C, Beetles U, Lim YY, Hurley E, Goligher J, Rahim R, Gagliardi TJ, Suaris T, Duffy SW.

Radiology. 2017 May;283(2):371-380. doi: 10.1148/radiol.2017151936. Epub 2017 Mar 13.

PMID:
28287917
46.

Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality.

Duffy SW, Etzioni R, Sasieni P.

Evid Based Med. 2017 Apr;22(2):76. doi: 10.1136/ebmed-2016-110632. Epub 2017 Feb 22. No abstract available.

PMID:
28228386
47.

Initiators and promoters for the occurrence of screen-detected breast cancer and the progression to clinically-detected interval breast cancer.

Yen AM, Wu WY, Tabar L, Duffy SW, Smith RA, Chen HH.

J Epidemiol. 2017 Mar;27(3):98-106. doi: 10.1016/j.je.2016.10.003. Epub 2016 Nov 28.

48.

Breast-Cancer Tumor Size and Screening Effectiveness.

Brentnall AR, Duffy SW, Cuzick J.

N Engl J Med. 2017 Jan 5;376(1):94. doi: 10.1056/NEJMc1614282. No abstract available.

PMID:
28052231
49.

Optimum low dose CT screening interval for lung cancer: the answer from NELSON?

Baldwin DR, Duffy SW, Devaraj A, Field JK.

Thorax. 2017 Jan;72(1):6-7. doi: 10.1136/thoraxjnl-2016-209011. Epub 2016 Oct 21. No abstract available.

PMID:
27974632
50.

A national cluster-randomised controlled trial to examine the effect of enhanced reminders on the socioeconomic gradient in uptake in bowel cancer screening.

Raine R, Moss SM, von Wagner C, Atkin W, Hans IK, Howe R, Solmi F, Morris S, Counsell N, Hackshaw A, Halloran S, Handley G, Logan RF, Rainbow S, Smith S, Snowball J, Seaman H, Thomas M, Smith SG, McGregor LM, Vart G, Wardle J, Duffy SW.

Br J Cancer. 2016 Dec 6;115(12):1479-1486. doi: 10.1038/bjc.2016.365. Epub 2016 Nov 22.

Supplemental Content

Loading ...
Support Center